Telomir Pharmaceuticals, INC. (TELO) — 8-K Filings

All 8-K filings from Telomir Pharmaceuticals, INC.. Browse 46 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (46)

Telomir Pharma Files 8-K on Agreements and Acquisitions — Apr 24, 2026 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on April 24, 2026, reporting on April 22, 2026, regarding a material definitive agreement, completion of an acquisiti
Telomir Pharmaceuticals Files 8-K — Mar 31, 2026 Risk: low
Telomir Pharmaceuticals, Inc. filed an 8-K on March 31, 2026, reporting other events as of March 30, 2026. The filing does not contain specific details on the n
Telomir Pharmaceuticals Reports Board and Executive Compensation Changes — Dec 22, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. announced on December 17, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the comp
8-K Filing — Dec 17, 2025
8-K Filing — Nov 24, 2025
8-K Filing — Nov 20, 2025
8-K Filing — Nov 12, 2025
Telomir Pharmaceuticals Files 8-K — Oct 22, 2025 Risk: medium
On October 22, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific detai
Telomir Pharmaceuticals Enters Material Definitive Agreement — Oct 20, 2025 Risk: medium
On October 17, 2025, Telomir Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Florida with its principal executi
Telomir Pharmaceuticals Files 8-K Report — Oct 14, 2025 Risk: low
On October 14, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific finan
Telomir Pharmaceuticals Files 8-K Report — Oct 8, 2025 Risk: low
On October 8, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is incorporated in Florida and its principal executive o
Telomir Pharmaceuticals Files 8-K Report — Oct 6, 2025 Risk: low
On October 6, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is inc
Telomir Pharmaceuticals Files 8-K Report — Sep 18, 2025 Risk: low
On September 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000 #1009, M
Telomir Pharmaceuticals Files 8-K — Sep 9, 2025 Risk: low
On September 9, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific deta
Telomir Pharmaceuticals Files 8-K — Sep 4, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on September 4, 2025, reporting an event on August 28, 2025. The filing is categorized under 'Other Events' and does
Telomir Pharmaceuticals Files 8-K — Aug 27, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
Telomir Pharmaceuticals Files 8-K — Aug 7, 2025 Risk: low
On August 7, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is involved in the pharmaceutical preparations indus
Telomir Pharmaceuticals Files 8-K Report — Jul 23, 2025 Risk: medium
On July 23, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
Telomir Pharmaceuticals Files 8-K: Other Events — Jul 22, 2025 Risk: medium
On July 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but provides no further specific details regar
Telomir Pharmaceuticals Files 8-K with Corporate Details — Jul 17, 2025 Risk: low
On July 17, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000 #1009, Miami,
Telomir Pharmaceuticals Files 8-K Report — Jun 18, 2025 Risk: medium
On June 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
Telomir Pharmaceuticals Files 8-K — Jun 11, 2025 Risk: low
On June 11, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns administrative details and does not disclose any new material
Telomir Pharmaceuticals Files 8-K Report — Jun 5, 2025 Risk: medium
On June 5, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not covere
Telomir Pharmaceuticals Files 8-K — Jun 2, 2025 Risk: medium
On June 2, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details r
Telomir Pharmaceuticals Files 8-K — May 29, 2025 Risk: low
On May 29, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located in Miami, Florida, and operates within the
Telomir Pharmaceuticals Reports Equity Sale — May 21, 2025 Risk: medium
On May 19, 2025, Telomir Pharmaceuticals, Inc. reported an unregistered sale of equity securities. The company also disclosed other events, though specific deta
Telomir Pharmaceuticals Files 8-K — May 15, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on May 15, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these eve
Telomir Pharmaceuticals Files 8-K — May 7, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these even
Telomir Pharmaceuticals Files 8-K — Mar 19, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on March 19, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these e
Telomir Pharmaceuticals Files 8-K Report — Feb 25, 2025 Risk: low
On February 25, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is incorporated in Florida and its principal executive
Telomir Pharmaceuticals Files 8-K — Feb 20, 2025 Risk: low
On February 20, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000 #1009, Mi
Telomir Pharmaceuticals Files 8-K — Feb 18, 2025 Risk: low
Telomir Pharmaceuticals, Inc. filed an 8-K on February 18, 2025, reporting "Other Events." The filing does not contain specific details about the nature of thes
Telomir Pharmaceuticals Files 8-K Report — Jan 28, 2025 Risk: medium
On January 28, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific detai
Telomir Pharmaceuticals Files 8-K — Jan 7, 2025 Risk: low
On January 7, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located at 100 SE 2nd St, Suite 2000, #1009, Mia
Telomir Pharmaceuticals Files 8-K — Dec 23, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on December 23, 2024, reporting "Other Events." The filing does not contain specific details about the nature of thes
Telomir Pharmaceuticals Changes Accountants — Dec 20, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. announced on December 16, 2024, a change in its certifying accountant. The company has dismissed its previous independent register
Telomir Pharmaceuticals Sells $500K in Stock — Dec 11, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. announced on December 9, 2024, that it entered into a securities purchase agreement for the sale of 1,000,000 shares of its common
Telomir Pharmaceuticals Files 8-K — Dec 2, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on December 2, 2024, reporting "Other Events." The filing does not contain specific details about the nature of these
Telomir Pharmaceuticals Announces Board and Officer Changes — Nov 21, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. announced on November 18, 2024, changes in its board of directors and officer appointments. Specifically, the company elected new
Telomir Pharmaceuticals Files 8-K — Nov 20, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on November 20, 2024, reporting "Other Events." The filing does not contain specific details about the nature of thes
Telomir Pharmaceuticals Enters Material Agreement with 03 Life Sciences — Sep 27, 2024 Risk: medium
On September 24, 2024, Telomir Pharmaceuticals, Inc. entered into a Material Definitive Agreement with 03 Life Sciences. This agreement involves a direct financ
Telomir Pharmaceuticals Files 8-K — Sep 3, 2024 Risk: low
Telomir Pharmaceuticals, Inc. filed an 8-K on September 3, 2024, reporting an "Other Events" item. The filing does not contain specific details about the event,
Telomir Pharmaceuticals Changes HQ, Reports Officer Compensation — Jun 24, 2024 Risk: low
Telomir Pharmaceuticals, Inc. announced on June 18, 2024, a change in its principal executive offices to Baltimore, Maryland. The company also reported on compe
Telomir Pharmaceuticals Files 8-K — Apr 15, 2024 Risk: low
Telomir Pharmaceuticals, Inc. filed an 8-K on April 15, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
Telomir Pharmaceuticals Appoints New Chief Medical Officer — Apr 12, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. announced on April 12, 2024, that its Board of Directors appointed Dr. Robert L. Smith as Chief Medical Officer, effective April 1
Telomir Pharma Enters Material Agreement — Feb 13, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. filed an 8-K on February 13, 2024, reporting an "Entry into a Material Definitive Agreement" that occurred on February 8, 2024. Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX